估算三阴性乳腺癌女性的死亡率:「ESTIMATE三阴性」工具
基于SEER数据库37,293例2010-2017年诊断的非转移性三阴性乳腺癌女性,采用Gray竞争风险法构建交互式工具ESTIMATE-TN,可估算诊断后0-7年乳腺癌特异性死亡与非乳腺癌死亡的累积风险。该工具整合患者与肿瘤特征,帮助理解竞争性死亡风险以辅助临床决策。
要点
- ESTIMATE-TN基于SEER 37,293例非转移性三阴性乳腺癌女性构建,可估算0-7年乳腺癌特异性死亡与非乳腺癌死亡累积风险。
- 示例:50-59岁T2N1高级别患者7年乳腺癌特异性死亡风险30.8%(95%CI 26.3-35.4%),非乳腺癌死亡风险2.8%(95%CI 1.3-4.3%)。
- 诊断后3年时,7年残余乳腺癌特异性死亡与非乳腺癌死亡累积风险分别为17.4%(95%CI 12.6-22.2%)与1.1%(95%CI 0-2.5%)。
核心结论
- ESTIMATE-TN是面向三阴性乳腺癌的交互式工具,可基于患者和肿瘤特征整合人群水平的乳腺癌特异性死亡与非乳腺癌死亡风险,帮助理解竞争性死亡风险,从而辅助临床决策。
研究设计与样本
- 利用监测、流行病学和最终结果(SEER)数据库,纳入2010-2017年诊断的37,293例三阴性乳腺癌女性,采用Gray子分布法构建交互式工具,非参数估算诊断后0-7年乳腺癌特异性死亡与非乳腺癌死亡的累积风险,并纳入基线临床和病理变量。
主要发现
- 多数患者为白人(71.9%),年龄50-69岁者占51.3%;肿瘤多为高级别(78.6%)、T2(42.4%)、N0(69.5%)。
- 50-59岁新诊断T2、N1、高级别三阴性乳腺癌患者7年乳腺癌特异性死亡风险为30.8%(95%CI 26.3-35.4%),同期非乳腺癌死亡风险为2.8%(95%CI 1.3-4.3%)。
- 诊断后3年时,7年残余乳腺癌特异性死亡累积风险为17.4%(95%CI 12.6-22.2%),残余非乳腺癌死亡累积风险为1.1%(95%CI 0-2.5%)。
关键数值与推荐
- ESTIMATE-TN允许输入患者和肿瘤特征以及期望的时间范围。
- 工具提供诊断后0至7年间乳腺癌特异性死亡与非乳腺癌死亡的累积风险非参数估计。
临床怎么用
- ESTIMATE-TN可基于患者和肿瘤特征整合乳腺癌特异性死亡与非乳腺癌死亡的人群风险,帮助理解竞争性死亡风险,从而辅助临床决策。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Triple-negative breast cancer (TNBC) is associated with a high risk of breast cancer-specific mortality (BCSM). Estimating the risk of BCSM and non-BCSM in TNBC would aid clinical decision-making. We developed the tool 'ESTIMATE-TN', to assess BCSM, non-BCSM, and all-cause mortality in non-metastatic TNBC. METHODS: Using Surveillance, Epidemiology, and End Results (SEER), we created an interactive tool that provides a nonparametric estimate of the cumulative risk of BCSM and non-BCSM between years 0 and 7 from diagnosis, accounting for baseline clinical and pathologic variables, using Gray's subdistribution method. RESULTS: We included 37,293 women with TNBC diagnosed during 2010-2017. Most patients were White (71.9%) and aged 50-69 years (51.3%). Most tumour characteristics were high-grade (78.6%), T2 (42.4%), and N0 (69.5%). ESTIMATE-TN allows to input patient and tumour characteristics, and the preferred timeframe. For example, patients aged 50-59 years with a new diagnosis of T2, N1, high-grade TNBC have a risk of BCSM at 7 years of 30.8% (95% confidence interval [CI]: 26.3-35.4%) and a risk of non-BCSM over the same period of 2.8% (95% CI: 1.3-4.3%). After 3 years from initial diagnosis, the residual cumulative risks of BCSM and non-BCSM at 7 years are 17.4% (95% CI: 12.6-22.2%) and 1.1% (95% CI: 0-2.5%), respectively. CONCLUSIONS: ESTIMATE-TN is an interactive tool for TNBC that can be used to integrate population-based risks of BCSM and non-BCSM based on patient and tumour characteristics, facilitating our understanding of competing risks of death, which can aid clinical decision-making.
引用
- Leone JP, Graham N, Leone J, et al. Estimating mortality in women with triple-negative breast cancer: The 'ESTIMATE triple-negative' tool. Eur J Cancer. 2023. PMID: 37356327. doi:10.1016/j.ejca.2023.05.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。